Russell Frank Company’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Russell Frank Company’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.74M	Buy	42,798 +12,386	+41%	+$426K	﹤0.01%	1917
2015 Q4	$1.26M	Buy	+30,412	New	+$1.02M	﹤0.01%	2095
2015 Q2	–	Sell	-38,562	Closed	-$881K	–	3109
2015 Q1	$881K	Buy	+38,562	New	+$973K	﹤0.01%	2204

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Russell Frank Company's FPRX Position: Q1 2016 in Review

Russell Frank Company increased its Five Prime Therapeutics, Inc. (FPRX) stake by 41% in Q1 2016, buying an estimated $426K and bringing the position to 42,798 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Russell Frank Company first reported a position in FPRX in Q1 2015 and has held it in 3 quarters since. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

Russell Frank Company held 42,798 shares of Five Prime Therapeutics, Inc. worth $1.74M as of Q1 2016.
Russell Frank Company bought 12,386 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $426K.
Five Prime Therapeutics, Inc. made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #1917 holding.
Russell Frank Company first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and has held it in 3 quarters since.
140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.